methylprednisolone sodium succinate

P3, N=50, Recruiting, The Hospital for Sick Children | Not yet recruiting --> Recruiting

P3, N=40, Recruiting, University Health Network, Toronto

P1/2, N=15, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Jan 2025 --> Sep 2026 | Trial primary completion date: Jan 2025 --> Sep 2026

P2, N=21, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Jun 2027 --> Jun 2028 | Initiation date: Jun 2024 --> Jan 2025 | Trial primary completion date: Jun 2027 --> Jun 2028

P2, N=20, Recruiting, St Vincent's Hospital, Sydney | Not yet recruiting --> Recruiting

P2, N=60, Recruiting, Cynata Therapeutics Limited | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Apr 2025 --> Oct 2025

P=N/A, N=178, The Third Xiangya Hospital of Central South University; The Third Xiangya Hospital of Central South University

P=N/A, N=220, West China Second University Hospital, Sichuan University; West China Second University Hospital, Sichuan University

P=N/A, N=110, Xi'an Children's Hospital; Xi'an Children's Hospital

P3, N=144, Recruiting, Huashan Hospital

P4, N=144, Not yet recruiting, Third Affiliated Hospital, Sun Yat-Sen University

P2, N=16, Not yet recruiting, Mayo Clinic | Trial completion date: Dec 2028 --> Mar 2029 | Initiation date: Dec 2024 --> Mar 2025 | Trial primary completion date: Dec 2027 --> Mar 2028

P2, N=40, Recruiting, Hoffmann-La Roche | Trial completion date: Mar 2029 --> Aug 2027 | Trial primary completion date: Mar 2026 --> Aug 2027

P3, N=3208, Active, not recruiting, Children's Hospital of Fudan University | Recruiting --> Active, not recruiting

P3, N=3208, Active, not recruiting, Children's Hospital of Fudan University | Recruiting --> Active, not recruiting

P2, N=25, Completed, Amgen | Phase classification: P2a --> P2

P3, N=359, Completed, Kite, A Gilead Company | Active, not recruiting --> Completed

The intravenous methylprednisolone, immunoglobulin, antibiotics and other symptomatic treatments helped the patient to recover full...Our report provides more evidence that anti-GluK2 antibodies may be pathogenic for the autoimmune encephalitis (cerebellitis). Immunotherapy can be used to treat it with good outcome.

P=N/A, N=20, Recruiting, University of Chicago | Trial primary completion date: May 2025 --> Sep 2025

P=N/A, N=5, Recruiting, The Alfred- Melbourne | Not yet recruiting --> Recruiting

P2, N=60, Enrolling by invitation, Cedars-Sinai Medical Center | Trial primary completion date: Oct 2024 --> Oct 2025

P1, N=20, Not yet recruiting, Baylor College of Medicine | Trial completion date: Oct 2028 --> Feb 2029 | Initiation date: Oct 2024 --> Feb 2025 | Trial primary completion date: Nov 2027 --> Mar 2028

P=N/A, N=70, Completed, Xuanwu Hospital, Beijing | Recruiting --> Completed

P2, N=80, Recruiting, University of Colorado, Denver | Not yet recruiting --> Recruiting

P2, N=40, Enrolling by invitation, Uppsala University Hospital | Trial completion date: May 2026 --> Dec 2028 | Trial primary completion date: Apr 2026 --> Apr 2028

P2, N=16, Not yet recruiting, Mayo Clinic

P2, N=80, Not yet recruiting, University of Colorado, Denver

P3, N=3200, Recruiting, Children's Hospital of Fudan University | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2024

P1/2, N=55, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Sep 2024 --> Sep 2025

P3, N=300, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

P3, N=50, Not yet recruiting, The Hospital for Sick Children

P1/2, N=24, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | N=10 --> 24

P2, N=200, Recruiting, AHS Cancer Control Alberta | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026

Intravenous methylprednisolone (IVMP) and plasma exchange resulted in partial improvement...In each episode, IVMP was to be partially effective with anti-IgE AAb reduction. Anti-IgE AAb may be a reasonable clinical indicator of increased disease activity in the sero-negative NMOSD associated with AD.

P2, N=1, Terminated, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N=30 --> 1 | Trial completion date: Oct 2021 --> Sep 2024 | Unknown status --> Terminated | Trial primary completion date: Oct 2021 --> Sep 2024; Participants recruitment failure

We experienced a case of pathologically diagnosed neurolymphomatosis with autonomic dysfunction associated with CLPD-NK. In cases of subacute to chronic autonomic dysfunction, paraneoplastic neuropathy, amyloidosis, and autoimmune autonomic ganglionopathy are considered; however neurolymphomatosis caused by CLPD-NK, an important cause of autonomic dysfunction, is not. In difficult to make diagnosis, aggressive nerve biopsy is required.

P3, N=1200, Active, not recruiting, Centre Hospitalier Universitaire Dijon | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2027 --> Feb 2024

Based on radiographic findings, a diagnosis of paraneoplastic LETM was made and he was treated acutely with IV methylprednisolone followed by a quick oral prednisone taper. However, he subsequently relapsed and symptomatically worsened while on rituximab therapy...Our observation of sustained disease response in this patient may support a role for concurrent BTK and BCL2 inhibition in paraneoplastic myelitis associated with B-cell lymphoproliferative disorders. However, this observation needs to be validated in larger cohort studies and potentially in clinical trials if further data are supportive.

In selected patients with permanently unresectable colorectal liver metastases, liver transplantation plus chemotherapy with organ allocation priority significantly improved survival versus chemotherapy alone. These results support the validation of liver transplantation as a new standard option for patients with permanently unresectable liver-only metastases.

P=N/A, N=50, Recruiting, Xuanwu Hospital, Beijing | Not yet recruiting --> Recruiting

He was started on intravenous methylprednisolone (subsequently transitioned to prednisone), methimazole, and metoprolol. Colchicine was subsequently added for the management of pericarditis and prednisone was continued (given concomitant thyroid disease) with a plan for tapering them off, per cardiology and endocrinology recommendations. A transthoracic echocardiogram revealed a small pericardial effusion...Thyroid ultrasound was nonsuggestive of Graves' disease. Thyrotoxicosis may present with a constellation of symptoms, including acute pericarditis. Timely recognition with EKG and echocardiography can aid in prompt management.

P=N/A, N=170, Completed, Xuanwu Hospital, Beijing | N=248 --> 170 | Trial completion date: Dec 2021 --> Jul 2024 | Trial primary completion date: Dec 2021 --> Jul 2024